{"title":"TSIX:一种新的长链非编码RNA在癌症发生和进展中的作用。","authors":"Yibei Gui, Jiale Zhao, Wei Wu, Xueqing Li, Lijun Wang, Hailin Wang, Yiyang Luo, Xueliang Ding, Xiaolan Li, Chengfu Yuan","doi":"10.2174/0113816128373990250609210655","DOIUrl":null,"url":null,"abstract":"<p><p>Long noncoding RNAs (LncRNAs) represent a group of long noncoding RNA molecules exceeding 200 nt in length and lacking the capacity for protein coding. In recent years, the function and progress of lncRNA have attracted the attention of more and more researchers. Specifically, the long non-coding RNA, TSIX (TSIX transcript, XIST antisense RNA), plays a significant role in ensuring random X-chromosome inactivation. Recent investigations have highlighted the involvement of lncRNA TSIX in the development of various cancers, emphasizing its crucial functions in tumorigenesis. TSIX has emerged as a novel cancerassociated lncRNA and it is identified for its aberrant expression in diverse tumors, such as those of the breast, gastric, hepatocellular, head and neck, lung, esophageal squamous cell, and uterine smooth muscle. Furthermore, lncRNA TSIX regulates mRNA expression by binding to specific miRNAs, utilizing a competitive endogenous RNA regulatory mechanism. This interaction significantly influences tumor cell proliferation, migration, invasion, and apoptosis. LncRNA TSIX may serve as a useful biomarker or a prospective therapeutic target in a variety of malignant cancers because of the biological functions and mechanisms associated with it.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"TSIX: A Novel Long Noncoding RNA in Cancer Development and Progression.\",\"authors\":\"Yibei Gui, Jiale Zhao, Wei Wu, Xueqing Li, Lijun Wang, Hailin Wang, Yiyang Luo, Xueliang Ding, Xiaolan Li, Chengfu Yuan\",\"doi\":\"10.2174/0113816128373990250609210655\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Long noncoding RNAs (LncRNAs) represent a group of long noncoding RNA molecules exceeding 200 nt in length and lacking the capacity for protein coding. In recent years, the function and progress of lncRNA have attracted the attention of more and more researchers. Specifically, the long non-coding RNA, TSIX (TSIX transcript, XIST antisense RNA), plays a significant role in ensuring random X-chromosome inactivation. Recent investigations have highlighted the involvement of lncRNA TSIX in the development of various cancers, emphasizing its crucial functions in tumorigenesis. TSIX has emerged as a novel cancerassociated lncRNA and it is identified for its aberrant expression in diverse tumors, such as those of the breast, gastric, hepatocellular, head and neck, lung, esophageal squamous cell, and uterine smooth muscle. Furthermore, lncRNA TSIX regulates mRNA expression by binding to specific miRNAs, utilizing a competitive endogenous RNA regulatory mechanism. This interaction significantly influences tumor cell proliferation, migration, invasion, and apoptosis. LncRNA TSIX may serve as a useful biomarker or a prospective therapeutic target in a variety of malignant cancers because of the biological functions and mechanisms associated with it.</p>\",\"PeriodicalId\":10845,\"journal\":{\"name\":\"Current pharmaceutical design\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current pharmaceutical design\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0113816128373990250609210655\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128373990250609210655","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
TSIX: A Novel Long Noncoding RNA in Cancer Development and Progression.
Long noncoding RNAs (LncRNAs) represent a group of long noncoding RNA molecules exceeding 200 nt in length and lacking the capacity for protein coding. In recent years, the function and progress of lncRNA have attracted the attention of more and more researchers. Specifically, the long non-coding RNA, TSIX (TSIX transcript, XIST antisense RNA), plays a significant role in ensuring random X-chromosome inactivation. Recent investigations have highlighted the involvement of lncRNA TSIX in the development of various cancers, emphasizing its crucial functions in tumorigenesis. TSIX has emerged as a novel cancerassociated lncRNA and it is identified for its aberrant expression in diverse tumors, such as those of the breast, gastric, hepatocellular, head and neck, lung, esophageal squamous cell, and uterine smooth muscle. Furthermore, lncRNA TSIX regulates mRNA expression by binding to specific miRNAs, utilizing a competitive endogenous RNA regulatory mechanism. This interaction significantly influences tumor cell proliferation, migration, invasion, and apoptosis. LncRNA TSIX may serve as a useful biomarker or a prospective therapeutic target in a variety of malignant cancers because of the biological functions and mechanisms associated with it.
期刊介绍:
Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field.
Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.